International journal of dermatology · 2016
Treatment of 100 chronic thalassemic leg wounds by plasma-rich platelets.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Afradi Hojjat, Saghaei Yassaman, Kachoei Zohre A, Babaei Vahid, Teimourian Shahram
Аннотация
OBJECTIVE: Thalassemia is a heterogeneous group of congenital hemoglobinopathies caused by mutations in the globin gene complex that result in an unbalanced globin synthesis. Unmatched globin chains bind to the cytosolic surface of red blood cell membrane where they cause oxidative damage that might in part be responsible for membrane weakness. The deformability of red blood cells and hypercoagulable state in thalassemic patients have been incriminated in leg ulcer formation, as this might cause ischemia to the skin and consequently friability and ulceration.
METHODS: Platelet-rich plasma (PRP) gel is considered an advanced wound therapy for chronic and acute wounds. PRP gel consists of cytokines, growth factors, chemokines, and a fibrin scaffold derived from a patient's blood. In this study, we treated 100 thalassemic leg wounds using PRP.
RESULTS: There was wound size reduction in patients after 4 weeks of treatment. In wounds with 2-3.5 cm2 surface area, complete closure happened after 12.5 weeks, 5-12 cm2 wounds completely closed after 13.2 weeks, and finally, 4.5-6 cm2 wounds healed completely after 14 weeks. None of the wounds reopened after 8 months of monitoring.
CONCLUSION: This study will help extrapolation of the use of PRP for at least thalassemic leg wound treatment.
METHODS: Platelet-rich plasma (PRP) gel is considered an advanced wound therapy for chronic and acute wounds. PRP gel consists of cytokines, growth factors, chemokines, and a fibrin scaffold derived from a patient's blood. In this study, we treated 100 thalassemic leg wounds using PRP.
RESULTS: There was wound size reduction in patients after 4 weeks of treatment. In wounds with 2-3.5 cm2 surface area, complete closure happened after 12.5 weeks, 5-12 cm2 wounds completely closed after 13.2 weeks, and finally, 4.5-6 cm2 wounds healed completely after 14 weeks. None of the wounds reopened after 8 months of monitoring.
CONCLUSION: This study will help extrapolation of the use of PRP for at least thalassemic leg wound treatment.